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IS WCA OF ONE MAJOR CORONARY ARTERY WITH 
THE CONTRALATERAL VESSEL OCCLUDED SAFE AND 
EFFECTIVE ? 
Fernando Grigera, Patrick L. Whitlow, Cleveland 
hi0. 
Attempted angioplasty (PTCA) of either a dominant right (RCA) or 
left anterior descending (LAD) coronary artery when the contralateral 
vesse; is occluded may trigger overwhelming LV dysfunction and 
hemodynamic collapse. We evaluated the risk vs benefit of PTCA.of a 
critical stenosis (>70%) of RCA (n=52) or LAD (n=143) in 195 paaents 
with the oonualatd curmary artery occluded. Left ventricular function 
(LVF) was normal (38%), mildly (34%), moderately (22%), or 
severely (6%) compromised in the study group. Data collected tncluded 
peripmcedure angiography and clinical results as well as both immediate 
and follow-up clinical status, repeat PTCA, coronary artery bypass graft 
surgery (CABG), acute myocardial infarction (AMI), and death. 
Immediate and late outcome (33fl8 months) of RCA PTCA and LAD 
PTCA was compared with 216 pts having PTCA of both the RCA and 
LAD and 195 pts who had coronary surgery (CABC), matched for 
VF, age (mean, 60 years), sex (75% male) and study period. 
, In the study group there were 7 emergency (3.6%) and 10 
elective CABG , 1 AMI (O.!i%), and 1 death (0.5%) in the hospital. 
After discharge. there were 33 elective CABG, 9 AMJ, and 9 death. 
There wen n5 tncrc deaths or AMI in the study group compared to the 
CABG or PTCA control groups, either petiprocedum or after discharge. 
Emergency CABG was necessary more frequently with PTCA of RCA 
(9.6%) than LAD (1.4%) @=.02). The study group had more elective 
CABG before (p=.O2) and after discharge (p=.OO4) than the control 
: 1) Dilating the LAD when the RCA is occluded is as 
safe as CABG; 2) Dilating the RCA when the LAD is occluded leads to 
more emergency CABG than LAD PTCA with RCA occlusion; 3) 
CABG did not improve the swival rate or the occurrence of AMI mom 
than PTCA, both in the hospital and during 3 year follow-up. 
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SJSTAINED EFFECT OF CAPTOPRIL ON THE ATTENUATION OF 
INFARCT EXPANSION FOLLOWING ACUTE MYOCARDIAL INFARCTION. 
Simon G. Ray, Keith G. Oldroyd*, Maurice kva*, 2 
Christie, Ian Ford+, Henry J. Dargie, Stuart M. Cobbe . 
Departments of Cardiology, Western and Royal* 
Infirmaries, GlaqJow. Department of Statistics+, 
University of Glasgow, U.K. 
In a double blind study 99 patients (82 male, aged 40-75) 
were randomly assigned to receive captoprillplacebo 
within 24 hrs of acute myocardial infarction and continue 
treatment for 1 year. There were no differences in 
clinical and echocardiographic variables between the 
groups at baseline except for an excess of previous MI in 
the placebo group 13/50 v 2149, p-0.002. After 12 months 
treatment 
increased 
LV end-diassolic volume index (EDVI) had 
8.4$1.9)ml/m in the captopril group vs 
19.0(2.6) ml/m with placebo, p=O.O02. LV end- ystolic 
volume index (ESVI) had increased2by 5.4(1.3)ml/m 2 in the 
captopril group vs 14.7(2.3)ml/m with placebo, p-0.001. 
The resulting mean volume indices were significa tly 
lower in thq captopril group: 9 vs 
89.5(3.1)ml/m2, p=o.oos, ESVI 
EDVI 76.9(3.0)ml$m 
47.0(3.8)ml/m vs 
53.9(3.4)ml/m , p=O.OOS, and LV ejection fraction was 
higher in the captopril group: 40.0(1.6)X vs 34.0(1.6)X, 
p=O.Ol. In the sub-group with anterior MI, anterior 
segment length (ASL) increased by 4(3)mm in the captopril 
group vs 17(4)x0 eith placebo, p=O.OOO, reeulting in a 
significantly shorter mean ASL with captopril: 91(5)mm vs 
107(4)mm, p-0.002. In the sub-group with infero-posterior 
MI, the PSL increased by 4(2)mm in the captopril group vs 
13(3)1um with placebo, ~~0.03. These changea indicate that 
captopril limita infarct expansion and LV dilatation for 
at least up to 1 year (after MI. 
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ASPIRIN USE BEFORE ONS 
FAILS TO RELUCE SHORT 
Ronald D. Gregor, B. 
Pentti M. Rautahar& 
Ross MacKenzie, 
Hermann K. Wolf 
Dalftousie University, Halifax Nova Scotia, Canada. 
Clinical data of 4,049 participants in the Halifax County Wf-iO 
MONICA project, consecutively admitted to CCU in 1984-86, were 
reviewed to determine the influence of acetylsalicylic acid (ASA) 
use before admission in patients diagnosed as definite myocardial 
infarction (Ml) by MONICA criteria, on short term mortality. 
Definfre Ml was found in 1,072 of the patients. Their mean age was 
59.9 years (f9.9). 73.8% were males, 51.9% had a history of 
coronary heat-l disease (CHD) and 9.6% were ta ASA at the time 
of admission. Within t there were 13 
deaths (12.6%) in the 1 atients taking ASA before admission, 
and 110 deaths (11.4%) in the 969 patients not on ASA before 
admission. 
Multivariate logistic regression analysis was performed to test 
the influence of ASA use before and during the hosuital admission, on 
28 day mortality. We controlled for age, sex, CHD history, diabeles, 
chest pain symptoms (whether absent, atypical, OP typical for MI), 
congestive heart failure on admission (CHF), CK enzyme rise, and 
stroke history. ASA use before presentation did not contribute 
itive or negative direction to 28 day mortality 
for odds ratio CL= 0.552, 3.225). ASA 
hospital phase was sfQni 
reduction (CL= 0.28. 0. 
Our results indicate that over 90% of this study group with a 
hfQh prior CHD prevalence did not take aspirin before CCU admis- 
sion for MI and that pre-admission use of ASA did not influence 
short term mortality. The observed beneficial effect of ASA in the 
acute MI setting is consistent with previous studies. 
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PILOT STUDY OF COMBINED ADMINISTRATION OF RIDOGREL AND 
rt-PA IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (MI) 
Hans J. Rapold, Frans Van de Werf*, Hilaire De Geest*, 
Wanida Sangtawesin, Els Vercammen+, D&sire Collen. 
Center for Thrombosis and Vascular Research and 'Depart- 
ment of Cardiology, University of Leuven, Leuven, Belgium; 
+Janssen Pharmaceutics, Beerse, Belgium 
The tolerance, safety and pharmacodynamics of a combined 
treatment of 100 mg rt-PA with 50 mg (group I, n=3), 150 
mg (group II, n=3), 300 mg (group III, n=8) and 450 mg 
(group IV, 
synthase 
n=3) of Ridogrel (R), a thromboxane (Tx)A2 
inhibitor/prostaglandin endoperoxide receptor 
antagonist, were studied and compared to 100 mg rt-PA + 
1,000 IU/h heparin (group V, n=8) in patients vith AMI. No 
major bleeding occurred despite bleeding times > 9 min in 
9/17 R-treated patients. Coronary patency at 5-10 days was 
obtained in 14/14 R-treated patients. Serum TxB levels 
decreased to 1% and 3% of baseline (p < 0.001) U!$min and 
12 hours after R. 6-keto-PGF and PGF levels increased 
3-fold (p < 0.001) and PGE 
1 
&'vels 25-&d (p C 0.001) in 
R-treated patients (groups -IV), suggesting a reorienta- 
tion of the prostaglandin synthesis towards endothelial 
antiaggregatory prostaglandins. The C% of the synthetic 
endoperoxide analogue U46619 for inducing ex vivo platelet 
aggregation increased from 0.5 uM at baseline to 4.0 pM 
with 150-450 mg R (groups ii-iv). 
We conclude that R is sufficiently safe and pharmacol- 
ogically effective to justify further clinical investiga- 
tion of its potential as an adjuvant treatment to 
accelerate and sustain coronary artery thrombolysis with 
rt-PA in patients with AMI. 
